Last reviewed · How we verify

Emtricitabine / Tenofovir Disoproxil Oral Tablet

University of Chicago · FDA-approved active Small molecule

Emtricitabine / Tenofovir Disoproxil Oral Tablet is a Nucleoside/nucleotide reverse transcriptase inhibitor combination Small molecule drug developed by University of Chicago. It is currently FDA-approved for HIV-1 infection treatment (as part of combination antiretroviral therapy), HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals. Also known as: Truvada, PrEP.

Emtricitabine and tenofovir disoproxil are nucleoside/nucleotide reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.

Emtricitabine and tenofovir disoproxil are nucleoside/nucleotide reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA. Used for HIV-1 infection treatment (as part of combination antiretroviral therapy), HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals.

At a glance

Generic nameEmtricitabine / Tenofovir Disoproxil Oral Tablet
Also known asTruvada, PrEP
SponsorUniversity of Chicago
Drug classNucleoside/nucleotide reverse transcriptase inhibitor combination
TargetHIV-1 reverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhaseFDA-approved

Mechanism of action

Emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) are antiretroviral agents that work synergistically to suppress HIV-1 replication. Both drugs inhibit reverse transcriptase, the viral enzyme essential for HIV to integrate into host cell DNA. This combination is commonly used as part of highly active antiretroviral therapy (HAART) regimens and is also approved for pre-exposure prophylaxis (PrEP) to prevent HIV acquisition in at-risk individuals.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Emtricitabine / Tenofovir Disoproxil Oral Tablet

What is Emtricitabine / Tenofovir Disoproxil Oral Tablet?

Emtricitabine / Tenofovir Disoproxil Oral Tablet is a Nucleoside/nucleotide reverse transcriptase inhibitor combination drug developed by University of Chicago, indicated for HIV-1 infection treatment (as part of combination antiretroviral therapy), HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals.

How does Emtricitabine / Tenofovir Disoproxil Oral Tablet work?

Emtricitabine and tenofovir disoproxil are nucleoside/nucleotide reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.

What is Emtricitabine / Tenofovir Disoproxil Oral Tablet used for?

Emtricitabine / Tenofovir Disoproxil Oral Tablet is indicated for HIV-1 infection treatment (as part of combination antiretroviral therapy), HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals.

Who makes Emtricitabine / Tenofovir Disoproxil Oral Tablet?

Emtricitabine / Tenofovir Disoproxil Oral Tablet is developed and marketed by University of Chicago (see full University of Chicago pipeline at /company/university-of-chicago).

Is Emtricitabine / Tenofovir Disoproxil Oral Tablet also known as anything else?

Emtricitabine / Tenofovir Disoproxil Oral Tablet is also known as Truvada, PrEP.

What drug class is Emtricitabine / Tenofovir Disoproxil Oral Tablet in?

Emtricitabine / Tenofovir Disoproxil Oral Tablet belongs to the Nucleoside/nucleotide reverse transcriptase inhibitor combination class. See all Nucleoside/nucleotide reverse transcriptase inhibitor combination drugs at /class/nucleoside-nucleotide-reverse-transcriptase-inhibitor-combination.

What development phase is Emtricitabine / Tenofovir Disoproxil Oral Tablet in?

Emtricitabine / Tenofovir Disoproxil Oral Tablet is FDA-approved (marketed).

What are the side effects of Emtricitabine / Tenofovir Disoproxil Oral Tablet?

Common side effects of Emtricitabine / Tenofovir Disoproxil Oral Tablet include Nausea, Diarrhea, Headache, Fatigue, Renal impairment (tenofovir-related), Bone density loss (tenofovir-related).

What does Emtricitabine / Tenofovir Disoproxil Oral Tablet target?

Emtricitabine / Tenofovir Disoproxil Oral Tablet targets HIV-1 reverse transcriptase and is a Nucleoside/nucleotide reverse transcriptase inhibitor combination.

Related